

ExonHit strengthens its intellectual property position in the US

- USPTO reaffirms the validity of core SpliceArray™ patent

Paris, France – October 26, 2009 – ExonHit is pleased to announce that the United States Patent and Trademark Office (“USPTO”) notified the Company of its intent to issue a Re-examination Certificate in connection with ExonHit’s US Patent n° 6,881,571 directed to the use of its SpliceArray™ technology.

The validity of this patent had been challenged as a defense in a patent infringement lawsuit initiated by ExonHit in 2007 against Jivan Biologics, Inc. (Jivan) before the US District Court for the Northern District of California. As often occurs in patent litigation in the United States, Jivan petitioned the USPTO to re-examine the validity of ExonHit’s patent. The USPTO granted Jivan Biologic’s petition in 2008, and the Court stayed the lawsuit pending the outcome of the re-examination.

“This decision by the USPTO strengthens ExonHit’s IP position and the validity of this patent has been confirmed for the second time in the US. ExonHit holds an equivalent European patent that was granted by the European Patent Office without opposition,” commented Dr. Loïc Maurel, M.D., President of the Management Board of ExonHit Therapeutics. “This decision rewards ExonHit’s determination to defend its intellectual property.”

All rejections have been withdrawn and all claims are allowed, in view of clarifying amendments made to two of the claims.

The USPTO Notice will be followed by the publication of a Re-examination Certificate. Additionally, the California litigation may resume and the case be disposed of by the Court.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

ExonHit Therapeutics**Media Contact**

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com

ALIZE RP

Caroline Carmagnol
+ 33 6 64 18 99 59
caroline@alizerp.com

Investor Contact

Loïc Maurel
+33 1 53 94 77 00
loic.maurel@exonhit.com